{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T16:32:26Z","timestamp":1786984346850,"version":"build-2736575974"},"reference-count":135,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annals of Diagnostic Pathology"],"published-print":{"date-parts":[[2022,2]]},"DOI":"10.1016\/j.anndiagpath.2021.151865","type":"journal-article","created":{"date-parts":[[2021,11,17]],"date-time":"2021-11-17T11:52:57Z","timestamp":1637149977000},"page":"151865","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"special_numbering":"C","title":["Specialized pro-resolving receptors are expressed in salivary glands with Sj\u00f6gren's syndrome"],"prefix":"10.1016","volume":"56","author":[{"given":"Harim Tavares","family":"dos Santos","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kihoon","family":"Nam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frank","family":"Maslow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bryan","family":"Trump","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olga J.","family":"Baker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.anndiagpath.2021.151865_bb0005","first-page":"259","article-title":"One year in review 2015: Sjogren's syndrome","volume":"33","author":"Luciano","year":"2015","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.anndiagpath.2021.151865_bb0010","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1093\/rheumatology\/keh647","article-title":"Sjogren's syndrome and the danger model","volume":"44","author":"Bredberg","year":"2005","journal-title":"Rheumatology (Oxford)"},{"issue":"vii","key":"10.1016\/j.anndiagpath.2021.151865_bb0015","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1016\/j.rdc.2008.08.004","article-title":"New concepts in the pathogenesis of Sjogren's syndrome","volume":"34","author":"Delaleu","year":"2008","journal-title":"Rheumatic diseases clinics of North America"},{"key":"10.1016\/j.anndiagpath.2021.151865_bb0020","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1111\/j.1600-0722.2004.00183.x","article-title":"Sjogren's syndrome","volume":"113","author":"Delaleu","year":"2005","journal-title":"Eur J Oral Sci"},{"key":"10.1016\/j.anndiagpath.2021.151865_bb0025","first-page":"3","article-title":"Sjogren's syndrome: mechanisms of pathogenesis involve interaction of immune and neurosecretory systems","author":"Fox","year":"2002","journal-title":"Scand J Rheumatol Suppl."},{"key":"10.1016\/j.anndiagpath.2021.151865_bb0030","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1034\/j.1601-0825.2002.02846.x","article-title":"Current issues in Sjogren's syndrome","volume":"8","author":"Jonsson","year":"2002","journal-title":"Oral Dis"},{"key":"10.1016\/j.anndiagpath.2021.151865_bb0035","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1146\/annurev-pathol-012513-104728","article-title":"Sjogren's syndrome","volume":"9","author":"Mavragani","year":"2014","journal-title":"Annu Rev Pathol"},{"issue":"Suppl 3","key":"10.1016\/j.anndiagpath.2021.151865_bb0040","first-page":"iii3","article-title":"Epidemiology of connective tissue disorders","volume":"45","author":"Gaubitz","year":"2006","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.anndiagpath.2021.151865_bb0045","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.jaut.2011.12.006","article-title":"Classification criteria for Sjogren's syndrome: a critical review","volume":"39","author":"Baldini","year":"2012","journal-title":"J Autoimmun"},{"key":"10.1016\/j.anndiagpath.2021.151865_bb0050","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1016\/0030-4220(75)90108-5","article-title":"The oral component of Sjogren's syndrome","volume":"39","author":"Daniels","year":"1975","journal-title":"Oral Surg Oral Med Oral Pathol"},{"key":"10.1016\/j.anndiagpath.2021.151865_bb0055","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1177\/10454411930040050201","article-title":"Current status of histogenetic and morphogenetic concepts of salivary gland tumorigenesis","volume":"4","author":"Dardick","year":"1993","journal-title":"Crit Rev Oral Biol Med"},{"key":"10.1016\/j.anndiagpath.2021.151865_bb0060","first-page":"56","article-title":"Diagnostic utility of major salivary gland ultrasonography in primary Sjogren's syndrome","volume":"33","author":"Hammenfors","year":"2015","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.anndiagpath.2021.151865_bb0065","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1177\/088307389901400906","article-title":"Clinical features and revised diagnostic criteria in Joubert syndrome","volume":"14","author":"Maria","year":"1999","journal-title":"J Child Neurol."},{"key":"10.1016\/j.anndiagpath.2021.151865_bb0070","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/S0065-2776(08)60641-0","article-title":"Antinuclear antibodies: diagnostic markers for autoimmune diseases and probes for cell biology","volume":"44","author":"Tan","year":"1989","journal-title":"Adv Immunol"},{"key":"10.1016\/j.anndiagpath.2021.151865_bb0075","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1902\/jop.2009.080350","article-title":"Periodontal conditions of individuals with Sjogren's syndrome","volume":"80","author":"Antoniazzi","year":"2009","journal-title":"J Periodontol"},{"key":"10.1016\/j.anndiagpath.2021.151865_bb0080","first-page":"387","article-title":"Oral involvement in patients with primary Sjogren's syndrome. Multidisciplinary care by dentists and rheumatologists","volume":"11","author":"Lopez-Pintor","year":"2015","journal-title":"Reumatol Clin"},{"key":"10.1016\/j.anndiagpath.2021.151865_bb0085","first-page":"300","article-title":"Prevalence, density, and manifestations of oral Candida albicans in patients with Sjogren's syndrome","volume":"26","author":"Rhodus","year":"1997","journal-title":"J Otolaryngol"},{"key":"10.1016\/j.anndiagpath.2021.151865_bb0090","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1007\/s00106-009-1903-6","article-title":"Recurrent abcesses of the parotid gland in Sjogren's syndrome","volume":"57","author":"Knopf","year":"2009","journal-title":"HNO"},{"key":"10.1016\/j.anndiagpath.2021.151865_bb0095","doi-asserted-by":"crossref","first-page":"430","DOI":"10.4103\/0377-4929.81621","article-title":"Sjogren's syndrome complicated by non-Hodgkin's lymphoma: spectrum of lymphoid proliferations and associated hepatitis C virus infection","volume":"54","author":"Awasthi","year":"2011","journal-title":"Indian J Pathol Microbiol"},{"key":"10.1016\/j.anndiagpath.2021.151865_bb0100","doi-asserted-by":"crossref","first-page":"E20","DOI":"10.1177\/014556131109001021","article-title":"Bilateral multicystic parotid masses in primary Sjogren syndrome","volume":"90","author":"Toh","year":"2011","journal-title":"Ear Nose Throat J"},{"key":"10.1016\/j.anndiagpath.2021.151865_bb0105","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1186\/1477-7525-7-46","article-title":"Primary Sjogren's syndrome: health experiences and predictors of health quality among patients in the United States","volume":"7","author":"Segal","year":"2009","journal-title":"Health Qual Life Outcomes"},{"key":"10.1016\/j.anndiagpath.2021.151865_bb0110","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1038\/nrrheum.2013.110","article-title":"Advances in understanding the pathogenesis of primary Sjogren's syndrome","volume":"9","author":"Nocturne","year":"2013","journal-title":"Nat Rev Rheumatol"},{"key":"10.1016\/j.anndiagpath.2021.151865_bb0115","first-page":"161","article-title":"One year in review 2016: Sjogren's syndrome","volume":"34","author":"Ferro","year":"2016","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.anndiagpath.2021.151865_bb0120","first-page":"45","article-title":"E-selectin in the pathogenesis of experimental myocardial ischemia-reperfusion injury","volume":"270","author":"Altavilla","year":"1994","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.anndiagpath.2021.151865_bb0125","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1111\/j.1445-5994.1992.tb04869.x","article-title":"Sjogren's syndrome: review with recent insights into immunopathogenesis","volume":"22","author":"Aziz","year":"1992","journal-title":"Aust N Z J Med"},{"key":"10.1016\/j.anndiagpath.2021.151865_bb0130","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1111\/j.0300-9475.2004.01508.x","article-title":"A dual role for interferon-gamma in the pathogenesis of Sjogren's syndrome-like autoimmune exocrinopathy in the nonobese diabetic mouse","volume":"60","author":"Cha","year":"2004","journal-title":"Scand J Immunol"},{"key":"10.1016\/j.anndiagpath.2021.151865_bb0135","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1016\/S0889-857X(21)00314-8","article-title":"Pathogenesis of Sjogren's syndrome","volume":"18","author":"Fox","year":"1992","journal-title":"Rheum Dis Clin North Am"},{"key":"10.1016\/j.anndiagpath.2021.151865_bb0140","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/S0049-0172(95)80025-5","article-title":"The etiopathogenesis of Sjogren's syndrome","volume":"25","author":"Price","year":"1995","journal-title":"Semin Arthritis Rheum"},{"key":"10.1016\/j.anndiagpath.2021.151865_bb0145","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1111\/adj.12023","article-title":"Stimulating the discussion on saliva substitutes: a clinical perspective","volume":"58","author":"Dost","year":"2013","journal-title":"Aust Dent J"},{"key":"10.1016\/j.anndiagpath.2021.151865_bb0150","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.tripleo.2003.07.010","article-title":"An update of the etiology and management of xerostomia","volume":"97","author":"Porter","year":"2004","journal-title":"Oral Surg Oral Med Oral Pathol Oral Radiol Endod"},{"key":"10.1016\/j.anndiagpath.2021.151865_bb0155","first-page":"E8","article-title":"Clinical evaluation of a new artificial saliva in spray form for patients with dry mouth","volume":"14","author":"Silvestre","year":"2009","journal-title":"Med Oral Patol Oral Cir Bucal"},{"key":"10.1016\/j.anndiagpath.2021.151865_bb0160","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1111\/odi.12105","article-title":"Oral manifestations and their treatment in Sj\u00f6gren's syndrome","volume":"20","author":"Gonz\u00e1lez","year":"2014","journal-title":"Oral Dis"},{"key":"10.1016\/j.anndiagpath.2021.151865_bb0165","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1111\/j.1601-5037.2008.00326.x","article-title":"Comparison of the effects of pilocarpine and cevimeline on salivary flow","volume":"7","author":"Braga","year":"2009","journal-title":"Int J Dent Hyg"},{"key":"10.1016\/j.anndiagpath.2021.151865_bb0170","doi-asserted-by":"crossref","first-page":"39","DOI":"10.2739\/kurumemedj.56.39","article-title":"Effects of cevimeline on the immunolocalization of aquaporin-5 and the ultrastructure of salivary glands in Sj\u00f6gren's syndrome model mice","volume":"56","author":"Nishimura","year":"2009","journal-title":"Kurume Med J"},{"key":"10.1016\/j.anndiagpath.2021.151865_bb0175","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1001\/jama.2010.1014","article-title":"Treatment of primary Sj\u00f6gren syndrome: a systematic review","volume":"304","author":"Ramos-Casals","year":"2010","journal-title":"JAMA"},{"key":"10.1016\/j.anndiagpath.2021.151865_bb0180","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.ijpharm.2009.09.007","article-title":"Dosage form design and in vitro\/in vivo evaluation of cevimeline extended-release tablet formulations","volume":"383","author":"Tajiri","year":"2010","journal-title":"Int J Pharm"},{"key":"10.1016\/j.anndiagpath.2021.151865_bb0185","doi-asserted-by":"crossref","first-page":"192","DOI":"10.17116\/oftalma2019135052192","article-title":"Lukina SS","volume":"135","author":"Safonova","year":"2019","journal-title":"Vestn Oftalmol"},{"key":"10.1016\/j.anndiagpath.2021.151865_bb0190","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaut.2019.102335","article-title":"Autoimmune epithelitis (Sjogren's syndrome); the impact of metabolic status of glandular epithelial cells on auto-immunogenicity","volume":"104","author":"Katsiougiannis","year":"2019","journal-title":"J Autoimmun"},{"key":"10.1016\/j.anndiagpath.2021.151865_bb0195","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaut.2019.102315","article-title":"Epigenetic perspectives on systemic autoimmune disease","volume":"104","author":"Karagianni","year":"2019","journal-title":"J Autoimmun"},{"key":"10.1016\/j.anndiagpath.2021.151865_bb0200","doi-asserted-by":"crossref","first-page":"17571","DOI":"10.1038\/s41598-017-17931-9","article-title":"A functional variant in the OAS1 gene is associated with Sjogren's syndrome complicated with HBV infection","volume":"7","author":"Liu","year":"2017","journal-title":"Sci Rep"},{"key":"10.1016\/j.anndiagpath.2021.151865_bb0205","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.clim.2017.04.018","article-title":"Genetics of Sjogren's syndrome","volume":"182","author":"Teos","year":"2017","journal-title":"Clin Immunol"},{"key":"10.1016\/j.anndiagpath.2021.151865_bb0210","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1111\/j.0300-9475.2004.01432.x","article-title":"Circulating cytokines in primary Sjogren's syndrome determined by a multiplex cytokine array system","volume":"59","author":"Szodoray","year":"2004","journal-title":"Scand J Immunol"},{"key":"10.1016\/j.anndiagpath.2021.151865_bb0215","first-page":"411","article-title":"Circulating levels of Th1\/Th2 cytokines in patients with primary Sjogren's syndrome: correlation with clinical and immunological features","volume":"19","author":"Garcic-Carrasco","year":"2001","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.anndiagpath.2021.151865_bb0220","doi-asserted-by":"crossref","first-page":"185","DOI":"10.3109\/08916939209148458","article-title":"Cytokine expression in labial salivary glands from patients with primary Sjogren's syndrome","volume":"12","author":"Oxholm","year":"1992","journal-title":"Autoimmunity"},{"key":"10.1016\/j.anndiagpath.2021.151865_bb0225","doi-asserted-by":"crossref","first-page":"5532","DOI":"10.4049\/jimmunol.152.11.5532","article-title":"Cytokine mRNA expression in salivary gland biopsies of Sjogren's syndrome","volume":"152","author":"Fox","year":"1994","journal-title":"J Immunol"},{"key":"10.1016\/j.anndiagpath.2021.151865_bb0230","doi-asserted-by":"crossref","first-page":"2095","DOI":"10.3389\/fimmu.2019.02095","article-title":"Formyl peptide receptor 2 activation ameliorates dermal fibrosis and inflammation in bleomycin-induced scleroderma","volume":"10","author":"Park","year":"2019","journal-title":"Front Immunol"},{"key":"10.1016\/j.anndiagpath.2021.151865_bb0235","article-title":"Resolution metabolomes activated by hypoxic environment","author":"Norris","year":"201954895","journal-title":"Sci Adv"},{"key":"10.1016\/j.anndiagpath.2021.151865_bb0240","doi-asserted-by":"crossref","DOI":"10.3390\/ijms19061801","article-title":"Role of human macrophage polarization in inflammation during infectious diseases","volume":"19","author":"Atri","year":"2018","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.anndiagpath.2021.151865_bb0245","doi-asserted-by":"crossref","first-page":"1555","DOI":"10.1016\/j.ajpath.2018.04.003","article-title":"The G-protein-coupled receptor ALX\/Fpr2 regulates adaptive immune responses in mouse submandibular glands","volume":"188","author":"Wang","year":"2018","journal-title":"Am J Pathol"},{"key":"10.1016\/j.anndiagpath.2021.151865_bb0250","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.autrev.2010.08.015","article-title":"Autoimmunity and chronic inflammation - two clearance-related steps in the etiopathogenesis of SLE","volume":"10","author":"Munoz","year":"2010","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.anndiagpath.2021.151865_bb0255","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1002\/jcla.1860070309","article-title":"Expression of cell adhesion molecules in the salivary and lacrimal glands of Sjogren's syndrome","volume":"7","author":"Saito","year":"1993","journal-title":"J Clin Lab Anal"},{"key":"10.1016\/j.anndiagpath.2021.151865_bb0260","article-title":"Lipoxin A4 inhibits immune cell binding to salivary epithelium and vascular endothelium","author":"Chinthamani","year":"2011","journal-title":"Am J Physiol Cell Physiol"},{"key":"10.1016\/j.anndiagpath.2021.151865_bb0265","first-page":"39","article-title":"Vascular endothelium and lymphocyte adhesion molecules in minor salivary glands of patients with Sjogren's syndrome","volume":"37","author":"Aziz","year":"1992","journal-title":"J Clin Lab Immunol"},{"key":"10.1016\/j.anndiagpath.2021.151865_bb0270","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1007\/978-1-4939-8709-2_2","article-title":"Cellular and vascular components of tertiary lymphoid structures","volume":"1845","author":"Mueller","year":"2018","journal-title":"Methods Mol Biol"},{"key":"10.1016\/j.anndiagpath.2021.151865_bb0275","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1016\/j.rdc.2016.03.003","article-title":"Genetics in Sjogren syndrome","volume":"42","author":"Reksten","year":"2016","journal-title":"Rheum Dis Clin North Am"},{"key":"10.1016\/j.anndiagpath.2021.151865_bb0280","doi-asserted-by":"crossref","DOI":"10.1002\/rcr2.285","article-title":"Pleuritis associated with primary Sjogren syndrome","volume":"6","author":"Hosoda","year":"2018","journal-title":"Respirol Case Rep."},{"key":"10.1016\/j.anndiagpath.2021.151865_bb0285","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1007\/s11926-011-0207-5","article-title":"Vasculitis in Sjogren's syndrome","volume":"13","author":"Scofield","year":"2011","journal-title":"Curr Rheumatol Rep"},{"key":"10.1016\/j.anndiagpath.2021.151865_bb0290","doi-asserted-by":"crossref","first-page":"24244","DOI":"10.1038\/srep24244","article-title":"ALX\/FPR2 modulates anti-inflammatory responses in mouse submandibular gland","volume":"6","author":"Wang","year":"2016","journal-title":"Sci Rep"},{"key":"10.1016\/j.anndiagpath.2021.151865_bb0295","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.1093\/rheumatology\/kez072","article-title":"Aspirin triggered resolvin D1 reduces inflammation and restores saliva secretion in a Sjogren's syndrome mouse model","volume":"58","author":"Dean","year":"2019","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.anndiagpath.2021.151865_bb0300","doi-asserted-by":"crossref","first-page":"45525","DOI":"10.1038\/srep45525","article-title":"AT-RvD1 promotes resolution of inflammation in NOD\/ShiLtJ mice","volume":"7","author":"Wang","year":"2017","journal-title":"Sci Rep"},{"key":"10.1016\/j.anndiagpath.2021.151865_bb0305","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1016\/j.arcmed.2006.08.002","article-title":"Pathophysiology of Sjogren's syndrome","volume":"37","author":"Garcia-Carrasco","year":"2006","journal-title":"Arch Med Res"},{"issue":"Suppl 118","key":"10.1016\/j.anndiagpath.2021.151865_bb0310","first-page":"114","article-title":"Sicca\/Sjogren's syndrome triggered by PD-1\/PD-L1 checkpoint inhibitors. Data from the international ImmunoCancer registry (ICIR)","volume":"37","author":"Ramos-Casals","year":"2019","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.anndiagpath.2021.151865_bb0315","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1016\/S0140-6736(05)66990-5","article-title":"Sjogren's syndrome","volume":"366","author":"Fox","year":"2005","journal-title":"Lancet"},{"key":"10.1016\/j.anndiagpath.2021.151865_bb0320","article-title":"Sjogren's syndrome: old and new therapeutic targets","volume":"102364","author":"Mavragani","year":"2019","journal-title":"J Autoimmun"},{"key":"10.1016\/j.anndiagpath.2021.151865_bb0325","doi-asserted-by":"crossref","first-page":"18050","DOI":"10.1038\/s41598-018-36679-4","article-title":"Identification of specialized pro-resolving mediator clusters from healthy adults after intravenous low-dose endotoxin and omega-3 supplementation: a methodological validation","volume":"8","author":"Norris","year":"2018","journal-title":"Sci Rep"},{"key":"10.1016\/j.anndiagpath.2021.151865_bb0330","article-title":"Pro-resolving mediators promote resolution in a human skin model of UV-killed Escherichia coli-driven acute inflammation","volume":"3","author":"Motwani","year":"2018","journal-title":"JCIInsight"},{"key":"10.1016\/j.anndiagpath.2021.151865_bb0335","doi-asserted-by":"crossref","first-page":"1582","DOI":"10.3389\/fphar.2018.01582","article-title":"The protectin family of specialized pro-resolving mediators: potent immunoresolvents enabling innovative approaches to target obesity and diabetes","volume":"9","author":"Hansen","year":"2018","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.anndiagpath.2021.151865_bb0340","doi-asserted-by":"crossref","first-page":"2657","DOI":"10.1172\/JCI97943","article-title":"Resolvins in inflammation: emergence of the pro-resolving superfamily of mediators","volume":"128","author":"Serhan","year":"2018","journal-title":"J Clin Invest"},{"key":"10.1016\/j.anndiagpath.2021.151865_bb0345","article-title":"Specialized pro-resolving lipid mediators are differentially altered in peripheral blood of patients with multiple sclerosis and attenuate monocyte and blood-brain barrier dysfunction","author":"Kooij","year":"2019","journal-title":"Haematologica"},{"key":"10.1016\/j.anndiagpath.2021.151865_bb0350","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/j.mam.2017.03.005","article-title":"Structural elucidation and physiologic functions of specialized pro-resolving mediators and their receptors","volume":"58","author":"Chiang","year":"2017","journal-title":"Mol Aspects Med"},{"key":"10.1016\/j.anndiagpath.2021.151865_bb0355","doi-asserted-by":"crossref","first-page":"3090","DOI":"10.1096\/fj.13-248393","article-title":"Immunoresolving actions of oral resolvin D1 include selective regulation of the transcription machinery in resolution-phase mouse macrophages","volume":"28","author":"Recchiuti","year":"2014","journal-title":"FASEB J"},{"key":"10.1016\/j.anndiagpath.2021.151865_bb0360","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.plefa.2008.09.012","article-title":"Systems approach with inflammatory exudates uncovers novel anti-inflammatory and pro-resolving mediators","volume":"79","author":"Serhan","year":"2008","journal-title":"Prostaglandins Leukot Essent Fatty Acids"},{"key":"10.1016\/j.anndiagpath.2021.151865_bb0365","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1038\/nature13479","article-title":"Pro-resolving lipid mediators are leads for resolution physiology","volume":"510","author":"Serhan","year":"2014","journal-title":"Nature"},{"key":"10.1016\/j.anndiagpath.2021.151865_bb0370","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.mam.2017.03.001","article-title":"Discovery of specialized pro-resolving mediators marks the dawn of resolution physiology and pharmacology","volume":"58","author":"Serhan","year":"2017","journal-title":"Mol Aspects Med"},{"key":"10.1016\/j.anndiagpath.2021.151865_bb0375","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1096\/fj.201601222R","article-title":"Treating inflammation and infection in the 21st century: new hints from decoding resolution mediators and mechanisms","volume":"31","author":"Serhan","year":"2017","journal-title":"FASEB J"},{"issue":"Suppl 1","key":"10.1016\/j.anndiagpath.2021.151865_bb0380","first-page":"S200","article-title":"Endogenous pro-resolving and anti-inflammatory lipid mediators: a new pharmacologic genus","volume":"153","author":"Serhan","year":"2008","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.anndiagpath.2021.151865_bb0385","doi-asserted-by":"crossref","first-page":"9323","DOI":"10.1074\/jbc.M609212200","article-title":"Resolvin D1 and its aspirin-triggered 17R epimer. Stereochemical assignments, anti-inflammatory properties, and enzymatic inactivation","volume":"282","author":"Sun","year":"2007","journal-title":"J Biol Chem"},{"key":"10.1016\/j.anndiagpath.2021.151865_bb0390","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.3389\/fphar.2018.01273","article-title":"Lipoxin and resolvin receptors transducing the resolution of inflammation in cardiovascular disease","volume":"9","author":"Pirault","year":"2018","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.anndiagpath.2021.151865_bb0395","doi-asserted-by":"crossref","first-page":"5501","DOI":"10.3390\/ijms14035501","article-title":"Understanding resolvin signaling pathways to improve oral health","volume":"14","author":"Keinan","year":"2013","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.anndiagpath.2021.151865_bb0400","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/j.mehy.2008.03.026","article-title":"Endogenous pro-resolving and anti-inflammatory lipid mediators: the new hope of atherosclerotic diseases","volume":"71","author":"Chen","year":"2008","journal-title":"Med Hypotheses"},{"key":"10.1016\/j.anndiagpath.2021.151865_bb0405","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1111\/etp.12010","article-title":"Specialized pro-resolving mediators: wiring the circuitry of effector immune and tissue homeostasis","volume":"24","author":"Fredman","year":"2011","journal-title":"Endodontic Topics."},{"key":"10.1016\/j.anndiagpath.2021.151865_bb0410","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0001316","article-title":"Candida albicans modulates host defense by biosynthesizing the pro-resolving mediator resolvin E1","volume":"2","author":"Haas-Stapleton","year":"2007","journal-title":"PloS one."},{"key":"10.1016\/j.anndiagpath.2021.151865_bb0415","doi-asserted-by":"crossref","first-page":"4743","DOI":"10.1167\/iovs.08-2462","article-title":"Anti-angiogenesis effect of the novel anti-inflammatory and pro-resolving lipid mediators","volume":"50","author":"Jin","year":"2009","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1016\/j.anndiagpath.2021.151865_bb0420","series-title":"Prostaglandins, Leukotrienes and Essential Fatty Acids (PLEFA)","article-title":"Resolvin D3 multi-level proresolving actions are host protective during infection","author":"Norris","year":"2016"},{"key":"10.1016\/j.anndiagpath.2021.151865_bb0425","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.4049\/jimmunol.1103483","article-title":"Specialized proresolving mediators enhance human B cell differentiation to antibody-secreting cells","volume":"189","author":"Ramon","year":"2012","journal-title":"J Immunol"},{"key":"10.1016\/j.anndiagpath.2021.151865_bb0430","doi-asserted-by":"crossref","DOI":"10.1007\/s00011-016-0946-x","article-title":"The role of resolvin D1 in the regulation of inflammatory and catabolic mediators in osteoarthritis","author":"Benabdoune","year":"2016","journal-title":"Inflamm Res"},{"key":"10.1016\/j.anndiagpath.2021.151865_bb0435","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1038\/mi.2012.66","article-title":"Aspirin-triggered resolvin D1 reduces mucosal inflammation and promotes resolution in a murine model of acute lung injury","volume":"6","author":"Eickmeier","year":"2013","journal-title":"Mucosal Immunol"},{"key":"10.1016\/j.anndiagpath.2021.151865_bb0440","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1038\/labinvest.2013.80","article-title":"Resolvin D1 reduces deterioration of tight junction proteins by upregulating HO-1 in LPS-induced mice","volume":"93","author":"Xie","year":"2013","journal-title":"Lab Invest"},{"key":"10.1016\/j.anndiagpath.2021.151865_bb0445","doi-asserted-by":"crossref","DOI":"10.1155\/2013\/185715","article-title":"Resolvin D1 reverts lipopolysaccharide-induced TJ proteins disruption and the increase of cellular permeability by regulating IkappaBalpha signaling in human vascular endothelial cells","volume":"2013","author":"Zhang","year":"2013","journal-title":"Oxid Med Cell Longev"},{"key":"10.1016\/j.anndiagpath.2021.151865_bb0450","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.actbio.2017.02.020","article-title":"Aspirin-triggered resolvin D1-modified materials promote the accumulation of pro-regenerative immune cell subsets and enhance vascular remodeling","volume":"53","author":"Sok","year":"2017","journal-title":"Acta Biomater"},{"key":"10.1016\/j.anndiagpath.2021.151865_bb0455","doi-asserted-by":"crossref","first-page":"4043","DOI":"10.1096\/fj.201701493R","article-title":"New maresin conjugates in tissue regeneration pathway counters leukotriene D4-stimulated vascular responses","volume":"32","author":"Chiang","year":"2018","journal-title":"FASEB J"},{"key":"10.1016\/j.anndiagpath.2021.151865_bb0460","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1038\/labinvest.2017.114","article-title":"ResolvinD1 stimulates epithelial wound repair and inhibits TGF-beta-induced EMT whilst reducing fibroproliferation and collagen production","volume":"98","author":"Zheng","year":"2018","journal-title":"Lab Invest"},{"key":"10.1016\/j.anndiagpath.2021.151865_bb0465","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1111\/odi.12979","article-title":"Specialized pro-resolving lipid mediators in experimental periodontitis: a systematic review","volume":"25","author":"Osorio Parra","year":"2019","journal-title":"Oral Dis"},{"key":"10.1016\/j.anndiagpath.2021.151865_bb0470","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.plefa.2017.01.004","article-title":"Identification and profiling of specialized pro-resolving mediators in human tears by lipid mediator metabolomics","volume":"117","author":"English","year":"2017","journal-title":"Prostaglandins Leukot Essent Fatty Acids"},{"key":"10.1016\/j.anndiagpath.2021.151865_bb0475","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1016\/j.tins.2011.08.005","article-title":"Emerging roles of resolvins in the resolution of inflammation and pain","volume":"34","author":"Ji","year":"2011","journal-title":"Trends Neurosci"},{"key":"10.1016\/j.anndiagpath.2021.151865_bb0480","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1177\/0022034513519108","article-title":"Expression of resolvin D1 biosynthetic pathways in salivary epithelium","volume":"93","author":"Leigh","year":"2014","journal-title":"J Dent Res"},{"key":"10.1016\/j.anndiagpath.2021.151865_bb0485","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1146\/annurev.pathmechdis.3.121806.151409","article-title":"Anti-inflammatory and proresolving lipid mediators","volume":"3","author":"Serhan","year":"2008","journal-title":"Annu Rev Pathol"},{"key":"10.1016\/j.anndiagpath.2021.151865_bb0490","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1038\/s41467-017-02538-5","article-title":"Human macrophages differentially produce specific resolvin or leukotriene signals that depend on bacterial pathogenicity","volume":"9","author":"Werz","year":"2018","journal-title":"Nat Commun"},{"key":"10.1016\/j.anndiagpath.2021.151865_bb0495","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1038\/mi.2015.99","article-title":"Human milk proresolving mediators stimulate resolution of acute inflammation","volume":"9","author":"Arnardottir","year":"2016","journal-title":"Mucosal Immunol"},{"key":"10.1016\/j.anndiagpath.2021.151865_bb0500","article-title":"Regulation of inflammation by lipid mediators in oral diseases","author":"Sommakia","year":"2016","journal-title":"Oral Diseases"},{"key":"10.1016\/j.anndiagpath.2021.151865_bb0505","article-title":"DHA- and EPA-derived resolvins, protectins, and maresins in airway inflammation","author":"Duvall","year":"2015","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.anndiagpath.2021.151865_bb0510","doi-asserted-by":"crossref","DOI":"10.1096\/fj.201500155R","article-title":"Specialized proresolving lipid mediators in patients with coronary artery disease and their potential for clot remodeling","author":"Elajami","year":"2016","journal-title":"FASEB J"},{"key":"10.1016\/j.anndiagpath.2021.151865_bb0515","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.prostaglandins.2017.06.003","article-title":"The novel lipid mediator PD1n-3 DPA: an overview of the structural elucidation, synthesis, biosynthesis and bioactions","volume":"133","author":"Hansen","year":"2017","journal-title":"Prostaglandins Other Lipid Mediat"},{"key":"10.1016\/j.anndiagpath.2021.151865_bb0520","doi-asserted-by":"crossref","first-page":"2642","DOI":"10.1097\/CCM.0000000000001312","article-title":"Gene expression of proresolving lipid mediator pathways is associated with clinical outcomes in trauma patients","volume":"43","author":"Orr","year":"2015","journal-title":"Crit Care Med"},{"key":"10.1016\/j.anndiagpath.2021.151865_bb0525","doi-asserted-by":"crossref","first-page":"1520","DOI":"10.1902\/jop.2008.080231","article-title":"Controlling the resolution of acute inflammation: a new genus of dual anti-inflammatory and proresolving mediators","volume":"79","author":"Serhan","year":"2008","journal-title":"J Periodontol"},{"key":"10.1016\/j.anndiagpath.2021.151865_bb0530","doi-asserted-by":"crossref","first-page":"C1331","DOI":"10.1152\/ajpcell.00207.2011","article-title":"Resolvin D1 prevents TNF-\u03b1-mediated disruption of salivary epithelial formation","volume":"302","author":"Odusanwo","year":"2012","journal-title":"Am J Physiol Cell Physiol"},{"key":"10.1016\/j.anndiagpath.2021.151865_bb0535","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.1093\/rheumatology\/kez072","article-title":"Aspirin triggered resolvin D1 reduces inflammation and restores saliva secretion in a Sj\u00f6gren's syndrome mouse model","volume":"58","author":"Dean","year":"2019","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.anndiagpath.2021.151865_bb0540","doi-asserted-by":"crossref","first-page":"C178","DOI":"10.1152\/ajpcell.00284.2013","article-title":"ALX\/FPR2 receptor for RvD1 is expressed and functional in salivary glands","volume":"306","author":"Nelson","year":"2014","journal-title":"Am J Physiol Cell Physiol"},{"key":"10.1016\/j.anndiagpath.2021.151865_bb0545","doi-asserted-by":"crossref","DOI":"10.23937\/2469-5726\/1510027","article-title":"Aspirin-triggered resolvin D1 versus dexamethasone in the treatment of Sjogren's syndrome-like NOD\/ShiLtJ mice - a pilot study","volume":"1","author":"Easley","year":"2015","journal-title":"J Rheum Dis Treat"},{"key":"10.1016\/j.anndiagpath.2021.151865_bb0550","doi-asserted-by":"crossref","DOI":"10.14814\/phy2.12990","article-title":"AT-RvD1 combined with DEX is highly effective in treating TNF-alpha-mediated disruption of the salivary gland epithelium","volume":"4","author":"Easley","year":"2016","journal-title":"Physiol Rep"},{"key":"10.1016\/j.anndiagpath.2021.151865_bb0555","doi-asserted-by":"crossref","first-page":"C1331","DOI":"10.1152\/ajpcell.00207.2011","article-title":"Resolvin D1 prevents TNF-alpha-mediated disruption of salivary epithelial formation","volume":"302","author":"Odusanwo","year":"2012","journal-title":"Am J Physiol Cell Physiol"},{"key":"10.1016\/j.anndiagpath.2021.151865_bb0560","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1136\/jcp.21.5.656","article-title":"Labial salivary gland biopsy in Sj\u00f6gren's disease","volume":"21","author":"Chisholm","year":"1968","journal-title":"J Clin Pathol"},{"key":"10.1016\/j.anndiagpath.2021.151865_bb0565","doi-asserted-by":"crossref","DOI":"10.1152\/ajpcell.00207.2011","article-title":"Resolvin D1 prevents TNF-alpha-mediated disruption of salivary epithelial formation","author":"Odusanwo","year":"2012","journal-title":"Am J Physiol, Cell Physiol."},{"key":"10.1016\/j.anndiagpath.2021.151865_bb0570","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1016\/j.it.2007.02.007","article-title":"Resolvins and protectins in the termination program of acute inflammation","volume":"28","author":"Ariel","year":"2007","journal-title":"Trends Immunol"},{"key":"10.1016\/j.anndiagpath.2021.151865_bb0575","doi-asserted-by":"crossref","first-page":"22847","DOI":"10.1074\/jbc.M603766200","article-title":"Metabolic inactivation of resolvin E1 and stabilization of its anti-inflammatory actions","volume":"281","author":"Arita","year":"2006","journal-title":"J Biol Chem"},{"key":"10.1016\/j.anndiagpath.2021.151865_bb0580","doi-asserted-by":"crossref","first-page":"4345","DOI":"10.4049\/jimmunol.174.7.4345","article-title":"Molecular circuits of resolution: formation and actions of resolvins and protectins","volume":"174","author":"Bannenberg","year":"2005","journal-title":"J Immunol"},{"key":"10.1016\/j.anndiagpath.2021.151865_bb0585","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aaf7483","article-title":"Proresolving lipid mediators resolvin D1, resolvin D2, and maresin 1 are critical in modulating T cell responses","author":"Chiurchiu","year":"20168353111","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.anndiagpath.2021.151865_bb0590","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1038\/nm.3911","article-title":"Elucidation of novel 13-series resolvins that increase with atorvastatin and clear infections","volume":"21","author":"Dalli","year":"2015","journal-title":"Nat Med"},{"key":"10.1016\/j.anndiagpath.2021.151865_bb0595","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1016\/j.chembiol.2012.11.010","article-title":"Resolvin D3 and aspirin-triggered resolvin D3 are potent immunoresolvents","volume":"20","author":"Dalli","year":"2013","journal-title":"Chem Biol"},{"key":"10.1016\/j.anndiagpath.2021.151865_bb0600","doi-asserted-by":"crossref","first-page":"5902","DOI":"10.4049\/jimmunol.177.9.5902","article-title":"Resolvin D series and protectin D1 mitigate acute kidney injury","volume":"177","author":"Duffield","year":"2006","journal-title":"J Immunol"},{"key":"10.1016\/j.anndiagpath.2021.151865_bb0605","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1002\/rcm.3331","article-title":"Simultaneous lipidomic analysis of three families of bioactive lipid mediators leukotrienes, resolvins, protectins and related hydroxy-fatty acids by liquid chromatography\/electrospray ionisation tandem mass spectrometry","volume":"22","author":"Masoodi","year":"2008","journal-title":"Rapid Commun Mass Spectrom"},{"key":"10.1016\/j.anndiagpath.2021.151865_bb0610","article-title":"Lipid mediators in the resolution of inflammation","volume":"7","author":"Serhan","year":"2014","journal-title":"Cold Spring Harb Perspect Biol"},{"key":"10.1016\/j.anndiagpath.2021.151865_bb0615","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.cmet.2013.10.006","article-title":"Resolvins, specialized proresolving lipid mediators, and their potential roles in metabolic diseases","volume":"19","author":"Spite","year":"2014","journal-title":"Cell Metab"},{"key":"10.1016\/j.anndiagpath.2021.151865_bb0620","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1084\/jem.20170681","article-title":"Resolvins suppress tumor growth and enhance cancer therapy","volume":"215","author":"Sulciner","year":"2018","journal-title":"J Exp Med"},{"key":"10.1016\/j.anndiagpath.2021.151865_bb0625","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1038\/ncprheum0616","article-title":"New endogenous anti-inflammatory and proresolving lipid mediators: implications for rheumatic diseases","volume":"3","author":"Yacoubian","year":"2007","journal-title":"Nat Clin Pract Rheumatol"},{"key":"10.1016\/j.anndiagpath.2021.151865_bb0630","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1002\/cre2.260","article-title":"Predictive modeling of aspirin-triggered resolvin D1 pharmacokinetics for the study of Sj\u00f6gren's syndrome","volume":"6","author":"Yellepeddi","year":"2020","journal-title":"Clin Exp Dent Res"},{"key":"10.1016\/j.anndiagpath.2021.151865_bb0635","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1111\/cts.12930","article-title":"Predicting resolvin D1 pharmacokinetics in humans with physiologically-based pharmacokinetic modeling","volume":"14","author":"Yellepeddi","year":"2021","journal-title":"Clin Transl Sci"},{"key":"10.1016\/j.anndiagpath.2021.151865_bb0640","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1136\/ard.61.6.554","article-title":"Classification criteria for Sj\u00f6gren's syndrome: a revised version of the European criteria proposed by the American-European consensus group","volume":"61","author":"Vitali","year":"2002","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.anndiagpath.2021.151865_bb0645","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1136\/annrheumdis-2013-203953","article-title":"Classification criteria for Sjogren's syndrome: nothing ever stands still!","volume":"73","author":"Bowman","year":"2014","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.anndiagpath.2021.151865_bb0650","doi-asserted-by":"crossref","first-page":"1537","DOI":"10.1136\/annrheumdis-2013-204634","article-title":"The prognostic value of routinely performed minor salivary gland assessments in primary Sj\u00f6gren's syndrome","volume":"73","author":"Risselada","year":"2014","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.anndiagpath.2021.151865_bb0655","doi-asserted-by":"crossref","first-page":"3103","DOI":"10.1002\/art.30465","article-title":"Chitinases in the salivary glands and circulation of patients with Sj\u00f6gren's syndrome: macrophage harbingers of disease severity","volume":"63","author":"Greenwell-Wild","year":"2011","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.anndiagpath.2021.151865_bb0660","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1189\/jlb.0809563","article-title":"Leukotriene B4 mediates gammadelta T lymphocyte migration in response to diverse stimuli","volume":"87","author":"Costa","year":"2010","journal-title":"J Leukoc Biol"},{"key":"10.1016\/j.anndiagpath.2021.151865_bb0665","doi-asserted-by":"crossref","first-page":"11873","DOI":"10.1038\/s41598-018-30373-1","article-title":"Resolvin E1 attenuates murine psoriatic dermatitis","volume":"8","author":"Sawada","year":"2018","journal-title":"Sci Rep"},{"key":"10.1016\/j.anndiagpath.2021.151865_bb0670","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1084\/jem.20042031","article-title":"Stereochemical assignment, antiinflammatory properties, and receptor for the omega-3 lipid mediator resolvin E1","volume":"201","author":"Arita","year":"2005","journal-title":"J Exp Med"},{"key":"10.1016\/j.anndiagpath.2021.151865_bb0675","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.abd1453","article-title":"Agonist anti-ChemR23 mAb reduces tissue neutrophil accumulation and triggers chronic inflammation resolution","volume":"7","author":"Trilleaud","year":"2021","journal-title":"Sci Adv"}],"container-title":["Annals of Diagnostic Pathology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1092913421001659?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1092913421001659?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T20:34:36Z","timestamp":1761078876000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1092913421001659"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,2]]},"references-count":135,"alternative-id":["S1092913421001659"],"URL":"https:\/\/doi.org\/10.1016\/j.anndiagpath.2021.151865","relation":{},"ISSN":["1092-9134"],"issn-type":[{"value":"1092-9134","type":"print"}],"subject":[],"published":{"date-parts":[[2022,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Specialized pro-resolving receptors are expressed in salivary glands with Sj\u00f6gren's syndrome","name":"articletitle","label":"Article Title"},{"value":"Annals of Diagnostic Pathology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.anndiagpath.2021.151865","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"151865"}}